KLEIN JOSEPH III 4

4 · IONIS PHARMACEUTICALS INC · Filed Mar 5, 2026

Insider Transaction Report

Form 4

Period: 2026-03-03

IONIS PHARMACEUTICALS INCIONS

KLEIN JOSEPH III

Director

Transactions

Exercise/Conversion
Common Stock
2026-03-03$40.05/sh+12,000$480,600→ 28,346 total
Exercise/Conversion
Common Stock
2026-03-03$42.88/sh+4,000$171,520→ 32,346 total
Sale
Common Stock
[F1][F2]
2026-03-03$79.17/sh−13,526$1,070,908→ 18,820 total
Sale
Common Stock
[F1][F3]
2026-03-03$80.00/sh−6,794$543,486→ 12,026 total
Sale
Common Stock
[F1][F4]
2026-03-03$80.82/sh−1,012$81,788→ 11,014 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−12,000→ 0 total
Exercise: $40.05From: 2022-07-01Exp: 2031-06-30→ Common Stock (12,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−4,000→ 0 total
Exercise: $42.88From: 2021-07-01Exp: 2028-07-01→ Common Stock (4,000 underlying)

Holdings

Common Stock
[F5]
(indirect: by Son)
100

Footnotes (5)

[F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.615 to $79.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.65 to $80.63 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.67 to $81.025 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F5]The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Joseph Klein, III|2026-03-05

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT